P‐score in preoperative biopsies accurately predicts P‐score in final pathology at radical prostatectomy in patients with localized prostate cancer

• Published in: The Prostate Vol. 83; no. 9; pp. 831 - 839
• Main Authors: Röbeck, Pontus, Xu, Lidi, Ahmed, Dilruba, Dragomir, Anca, Dahlman, Pär, Häggman, Michael, Ladjevardi, Sam
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.06.2023
• Subjects: biomarker; Biopsy; Cancer surgery; core needle biopsy; Gene expression; Humans; Image-Guided Biopsy; Insulin-like growth factor-binding protein 3; Magnetic resonance imaging; Male; Neoplasm Grading; Neoplasm Staging; Pathology; prognosis; Prostate cancer; Prostatectomy; Prostatic Neoplasms - diagnostic imaging; Prostatic Neoplasms - genetics; Prostatic Neoplasms - surgery; Risk groups; Transcription Factors; Tumors; Urological surgery; prostatectomy; prostate cancer; biomarker; core needle biopsy; prognosis
• ISSN: 0270-4137; 1097-0045; 1097-0045
• DOI: 10.1002/pros.24523

Background Prostate cancer (PCa) is a highly heterogeneous, multifocal disease, and identification of clinically significant lesions is challenging, which complicates the choice of adequate treatment. The Prostatype® score (P‐score) is intended to guide treatment decisions for newly diagnosed PCa patients based on a three‐gene signature (IGFBP3, F3, and VGLL3) and clinicopathological information obtained at diagnosis. This study evaluated association of the P‐score measured in preoperative magnetic resonance imaging/transrectal ultrasound fusion‐guided core needle biopsies (CNBs) and the P‐score measured in radical prostatectomy (RP) specimens of PCa patients. We also evaluated the P‐score association with the pathology of RP specimens. Furthermore, concordance of the P‐score in paired CNB and RP specimens, as well as in index versus concomitant nonindex tumor foci from the same RP was investigated. Methods The study included 100 patients with localized PCa. All patients were diagnosed by CNB and underwent RP between 2015 and 2018. Gene expression was assessed with the Prostatype® real‐time quantitative polymerase chain reaction kit and the P‐score was calculated. Patients were categorized into three P‐score risk groups according to previously defined cutoffs. Results For 71 patients, sufficient CNB tumor material was available for comparison with the RP specimens. The CNB‐based P‐score was associated with the pathological T‐stage in RP specimens (p = 0.02). Moreover, the CNB‐based P‐score groups were in substantial agreement with the RP‐based P‐score groups (weighted κ score: 0.76 [95% confidence interval, 95% CI: 0.60–0.92]; Spearman's rank correlation coefficient r = 0.83 [95% CI: 0.74–0.89]; p < 0.0001). Similarly, the P‐score groups based on paired index tumor and concomitant nonindex tumor foci (n = 64) were also in substantial agreement (weighted κ score: 0.74 [95% CI: 0.57–0.91]; r = 0.83 [95% CI: 0.73–0.89], p < 0.0001). Conclusions Our findings suggest that the P‐score based on preoperative CNB accurately reflects the pathology of the whole tumor, highlighting its value as a decision support tool for newly diagnosed PCa patients.